Specifically, GLP-1RA users were associated with a higher risk of the development of NAFLD/NASH compared to current insulin users (aHR [95% CI]: 1.22 [0.91–1.63]) [18] but a decreased risk compared to current users of sulfonylureas (0.85 [0.64–1.13]) [18] or DPP4i (0.83 [0.66–1.63]) [19]. Here, INS is linked to metabolic dysfunction-associated steatohepatitis.